<DOC>
	<DOCNO>NCT00994994</DOCNO>
	<brief_summary>Tranexamic acid ( TXA ) antifibrinolytic agent reduce blood loss cardiac surgery . Previous seven RCTs compare effect TXA pediatric cardiac surgery show conflict result . The reason show mixed result would imbalance patient population regard presence cyanosis . TXA would reduce blood loss pediatric cardiac surgery well balance patient population .</brief_summary>
	<brief_title>Tranexamic Acid Pediatric Cardiac Surgery</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Heart Defects , Congenital</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>child undergo elective cardiac surgery cardiopulmonary bypass neonate bear within 1 month preoperative inotropes preoperative mechanical ventilation preexist coagulation disorder reoperation within 48 hour significant liver kidney disease know allergy TXA</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>pediatric cardiac surgery</keyword>
	<keyword>bleeding</keyword>
	<keyword>tranexamic acid</keyword>
	<keyword>fibrinolysis</keyword>
	<keyword>blood loss pediatric cardiac surgery</keyword>
</DOC>